Showing results (1-10 of 24) with videos related to
Sort By:
Pageof 3
AIDS Patient Care and Stds|September 17, 2005
Beyond efficacy: the impact of combination antiretroviral therapy on quality of lifePaul E Sax, Joseph C GatheCureus|November 20, 2020
COVID-19 Coexisting With the Human Immunodeficiency Virus: A Case ReportElizabeth Gamboa, Melanie Duran, Joseph C Gathe, et al.Stem Cells and Development|November 21, 2008
Cord blood stem cell therapy for acquired immune deficiency syndromeGabriel Gonzalez, Elizabeth J Shpall, Joseph C Gathe, et al.Journal of the International Association of Providers of AIDS Care|January 30, 2016
Fecal Transplantation for Clostridium Difficile-"All Stool May Not Be Created Equal"Joseph C Gathe, Efemena M Diejomaoh, Carl C Mayberry, et al.The AIDS Reader|October 23, 2004
Impact of resistance to antiretroviral therapy in the minority communityAllen E Rodriguez, Rafael E Campo, Joseph C Gathe, et al.HIV Clinical Trials|October 23, 2013
Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patientsRobin Wood, Joseph C Gathe, Naomi Givens, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2024
Efficacy and Safety of 2 Fixed Doses of Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced HIV-Positive IndividualsEdwin DeJesus, William J Towner, Joseph C Gathe, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 11, 2021
Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a StudyJoseph C Gathe, Robin L Hardwicke, Fernando Garcia, et al.Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|September 16, 2010
Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adultsRosa F Yeh, Bryan A Lipman, Carl Mayberry, et al.Antiviral Therapy|April 9, 2008
Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimensI-Chan Huang, Albert W Wu, Henrik W Finnern, et al.Pageof 3